The DOI matches its Crossref record.
Evaluation of naltrexone for dissociative symptoms in borderline personality disorder
Abstract
Data from a pilot study suggest that naltrexone might reduce dissociative symptoms in patients with borderline personality disorder. However, the interpretation of these data is limited by the lack of a control group and by the nonblind nature of this study. Hence, we examined the effects of naltrexone using a more rigorous design that controlled for major confounders such as spontaneous reduction of dissociation over time and placebo effects. Unmedicated patients with BPD [according to Diagnostic and Statistical Manual of Mental Disorders-IVth edition (DSM-IV)] were included in two small double-blind placebo-controlled randomized trials (total n=29). Patients received both 3 weeks of naltrexone (50 or 200 mg/day) and 3 weeks of placebo in a randomized order. Twenty-five patients completed the study according to protocol. Dissociation under naltrexone and placebo, respectively, was compared by repeated-measures analyses of variance. In either trial, both the intensity and duration of dissociative symptoms were numerically lower under naltrexone than under placebo. However, the effects were too small to reach statistical significance. Our data provide the first estimate of the pure pharmacological antidissociative efficacy of naltrexone from a rigorously designed trial.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“neither naloxone nor naltrexone performed better than placebo for dissociative symptoms in randomized controlled trials in borderline personality disorder samples [120,121].”
From Treatment of dissociative identity disorder: leveraging neurobiology to optimize success (2024) · cites this paper as [121]
In the citing paper
“neither naloxone nor naltrexone performed better than placebo for dissociative symptoms in randomized controlled trials in borderline personality disorder samples [120,121].”
From Treatment of dissociative identity disorder: leveraging neurobiology to optimize success (2024) · cites this paper as [120]
Citations
Cited by
The aetiology of psychogenic non‐epileptic seizures: risk factors and comorbidities
Popkirov, S., Asadi‐Pooya, A. A., Duncan, R., Gigineishvili, D., Hingray, C., Miguel Kanner, A., LaFrance, W. C., Pretorius, C., Reuber, M., & on behalf of the ILAE PNES Task Force (2019) · Epileptic Disorders · doi:10.1684/epd.2019.1107 · Cited by 195
Pharmacotherapy for Borderline Personality Disorder—Current Evidence and Recent Trends
Stoffers‐Winterling, J., & Lieb, K. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0534-0 · Cited by 129
Self-citationPharmacological interventions for people with borderline personality disorder
Stoffers‐Winterling, J., Storebø, O. J., Ribeiro, J. P., Kongerslev, M., Vӧllm, B., Mattivi, J. T., Faltinsen, E. G., Todorovac, A., Jørgensen, M. S., Edemann-Callesen, H., et al. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012956.pub2 · Cited by 154
Self-citationEndogenous opiates and behavior: 2012
Bodnar, R. J. (2013) · Peptides · doi:10.1016/j.peptides.2013.10.001 · Cited by 116
McKinnon, M. C., Boyd, J. E., Frewen, P. A., Lanius, U. F., Jetly, R., Richardson, J. D., & Lanius, R. A. (2016) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2016.07.017 · Cited by 94
Metadata
- Authors
- Schmahl, C., Kleindienst, N., Limberger, M., Ludäscher, P., Mauchnik, J., Deibler, P., Brünen, S., Hiemke, C., Lieb, K., Herpertz, S., Reicherzer, M., Berger, M., & Bohus, M.
- Affiliations
- Central Institute of Mental Health (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Heidelberg University (DE)
- Corresponding author
- Schmahl, Christian
- Kleindienst, Nikolaus
- ORCID
- Venue
- International Clinical Psychopharmacology
- Published
- 2012-01
- Volume
- 27
- Issue
- 1
- Pages
- 61-68
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2320426285
- Cited by
- 63
- References
- 0
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 6 · 2023: 3 · 2022: 3 · 2021: 2 · 2020: 2 · 2019: 11 · 2018: 2 · 2017: 6 · 2016: 6 · 2015: 4 · 2014: 3 · 2013: 6 · 2012: 2
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Personality Disorders and Psychopathology
- Health Sciences › Medicine › Psychiatry and Mental health › Psychosomatic Disorders and Their Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- naltrexone, borderline personality disorder, dissociative symptoms, pharmacotherapy
- MeSH terms
- Adolescent, Adult, Borderline Personality Disorder, Double-Blind Method, Female, Germany, Humans, Naltrexone, Narcotic Antagonists, Placebos, Psychiatric Status Rating Scales, Time Factors, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of naltrexone for dissociative symptoms in borderline personality disorder. https://app.cochat.ai/papers/10.1097/yic.0b013e32834d0e50
- The paper
- Schmahl, C., Kleindienst, N., Limberger, M., Ludäscher, P., Mauchnik, J., Deibler, P., Brünen, S., Hiemke, C., Lieb, K., Herpertz, S., Reicherzer, M., Berger, M., & Bohus, M. (2012). Evaluation of naltrexone for dissociative symptoms in borderline personality disorder. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0b013e32834d0e50
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.